Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Epigenetic regulation of RhoB loss of expression in lung cancer.

Mazières J, Tovar D, He B, Nieto-Acosta J, Marty-Detraves C, Clanet C, Pradines A, Jablons D, Favre G.

BMC Cancer. 2007 Nov 30;7:220.

2.

RhoB is frequently downregulated in non-small-cell lung cancer and resides in the 2p24 homozygous deletion region of a lung cancer cell line.

Sato N, Fukui T, Taniguchi T, Yokoyama T, Kondo M, Nagasaka T, Goto Y, Gao W, Ueda Y, Yokoi K, Minna JD, Osada H, Kondo Y, Sekido Y.

Int J Cancer. 2007 Feb 1;120(3):543-51.

3.

Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.

Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, Plass C.

J Natl Cancer Inst. 2006 Mar 15;98(6):396-406.

PMID:
16537832
4.

Epigenetic down-regulation of death-associated protein kinase in lung cancers.

Toyooka S, Toyooka KO, Miyajima K, Reddy JL, Toyota M, Sathyanarayana UG, Padar A, Tockman MS, Lam S, Shivapurkar N, Gazdar AF.

Clin Cancer Res. 2003 Aug 1;9(8):3034-41.

5.

Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line.

Wang S, Yan-Neale Y, Fischer D, Zeremski M, Cai R, Zhu J, Asselbergs F, Hampton G, Cohen D.

Oncogene. 2003 Sep 18;22(40):6204-13.

PMID:
13679859
6.

Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.

Tang X, Yin X, Xiang T, Li H, Li F, Chen L, Ren G.

Cancer Biomark. 2012-2013;12(1):11-9. doi: 10.3233/CBM-2012-00280.

PMID:
23321465
7.
8.

Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines.

Sekita N, Suzuki H, Ichikawa T, Kito H, Akakura K, Igarashi T, Nakayama T, Watanabe M, Shiraishi T, Toyota M, Yoshie O, Ito H.

Jpn J Cancer Res. 2001 Sep;92(9):947-51.

PMID:
11572762
9.

Silencing of miR-137 by aberrant promoter hypermethylation in surgically resected lung cancer.

Kang N, Choi SY, Kim YK, Yoo IeR, Han DH, Lee DS, Kim YS, Hong SH, Kang JH, Lee KY, Park JK, Sung SW, Park MS, Yim HW, Kim SJ, Park JY.

Lung Cancer. 2015 Aug;89(2):99-103. doi: 10.1016/j.lungcan.2015.05.011. Epub 2015 Jun 4.

PMID:
26101014
10.

Epigenetic inactivation of laminin-5-encoding genes in lung cancers.

Sathyanarayana UG, Toyooka S, Padar A, Takahashi T, Brambilla E, Minna JD, Gazdar AF.

Clin Cancer Res. 2003 Jul;9(7):2665-72.

11.

Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.

Zhang YW, Staal B, Dykema KJ, Furge KA, Vande Woude GF.

PLoS One. 2012;7(6):e38955. doi: 10.1371/journal.pone.0038955. Epub 2012 Jun 12.

12.

Expression loss and revivification of RhoB gene in ovary carcinoma carcinogenesis and development.

Liu Y, Song N, Ren K, Meng S, Xie Y, Long Q, Chen X, Zhao X.

PLoS One. 2013 Nov 1;8(11):e78417. doi: 10.1371/journal.pone.0078417. eCollection 2013.

13.

Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation.

Yue W, Dacic S, Sun Q, Landreneau R, Guo M, Zhou W, Siegfried JM, Yu J, Zhang L.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4336-44.

14.

Methylation and gene silencing of the Ras-related GTPase gene in lung and breast cancers.

Suzuki M, Shigematsu H, Shames DS, Sunaga N, Takahashi T, Shivapurkar N, Iizasa T, Minna JD, Fujisawa T, Gazdar AF.

Ann Surg Oncol. 2007 Apr;14(4):1397-404. Epub 2006 Dec 29.

PMID:
17195088
15.

Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer.

Virmani A, Rathi A, Sugio K, Sathyanarayana UG, Toyooka S, Kischel FC, Tonk V, Padar A, Takahashi T, Roth JA, Euhus DM, Minna JD, Gazdar AF.

Int J Cancer. 2003 Aug 20;106(2):198-204.

16.

Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.

El-Awady RA, Hersi F, Al-Tunaiji H, Saleh EM, Abdel-Wahab AH, Al Homssi A, Suhail M, El-Serafi A, Al-Tel T.

Cancer Biol Ther. 2015;16(7):1056-70. doi: 10.1080/15384047.2015.1046023.

17.

Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis.

Miao Y, Wang L, Zhang X, Xu X, Jiang G, Fan C, Liu Y, Lin X, Yu J, Zhang Y, Wang E.

PLoS One. 2014 Nov 14;9(11):e112258. doi: 10.1371/journal.pone.0112258. eCollection 2014.

18.

Decreased expression of connective tissue growth factor in non-small cell lung cancer is associated with clinicopathological variables and can be restored by epigenetic modifiers.

Drzewiecka H, Gałęcki B, Jarmołowska-Jurczyszyn D, Kluk A, Dyszkiewicz W, Jagodziński PP.

J Cancer Res Clin Oncol. 2016 Sep;142(9):1927-46. doi: 10.1007/s00432-016-2195-3. Epub 2016 Jul 8.

19.

IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.

Ibanez de Caceres I, Cortes-Sempere M, Moratilla C, Machado-Pinilla R, Rodriguez-Fanjul V, Manguán-García C, Cejas P, López-Ríos F, Paz-Ares L, de CastroCarpeño J, Nistal M, Belda-Iniesta C, Perona R.

Oncogene. 2010 Mar 18;29(11):1681-90. doi: 10.1038/onc.2009.454. Epub 2009 Dec 21.

PMID:
20023704
20.

ANKRD18A as a novel epigenetic regulation gene in lung cancer.

Liu WB, Han F, Jiang X, Yang LJ, Li YH, Liu Y, Chen HQ, Ao L, Cui ZH, Cao J, Liu JY.

Biochem Biophys Res Commun. 2012 Dec 14;429(3-4):180-5. doi: 10.1016/j.bbrc.2012.10.116. Epub 2012 Nov 3.

PMID:
23131552

Supplemental Content

Support Center